Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Divozilimab in Patients With Systemic Scleroderma

NCT05726630 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT05726630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05726630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Divozilimab in Patients With Systemic Scleroderma
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 26, 2022
Completion date
February 1, 2027
Enrollment
152 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

systemic scleroderma